ArticleFrontiers in oncology2023

Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective.

Wentao Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.